酞嗪-5,8-二酮 | 147088-71-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 酞嗪-5,8-二酮
• 英文名称: phthalazine-5,8-dione
• CAS: 147088-71-9
• 化学式: C₈H₄N₂O₂
• mdl: MFCD10699303
• 分子量: 160.132
• InChiKey: FGNJUOZCRMSPQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  59.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  酞嗪-5,8-二酮 在 氯 作用下， 以 四氯化碳 、 氯仿 为溶剂， 反应 1.0h， 以87%的产率得到6,7-二氯酞嗪-5,8-二酮
  参考文献：
  名称：

  Parrick, John; Ragunathan, Ramanaranjinie, Journal of the Chemical Society. Perkin transactions I, 1993, # 2, p. 211 - 216

  摘要：

  DOI：
• 作为产物：
  描述：

  2,3-二氮杂萘 在 potassium dichromate 、 硫酸 、 氢气 、 钯 、 potassium nitrate 作用下， 以 甲醇 为溶剂， 生成 酞嗪-5,8-二酮
  参考文献：
  名称：

  Ezrin inhibitors and methods of making and using

  摘要：

  该发明涵盖了包含以下化合物的化合物和药物组合物（I）的药物组合物，或其药用盐或前药，这些化合物对于抑制细胞中的ezrin蛋白或抑制癌细胞的生长是有用的。

  公开号：

  US09522908B2

文献信息

• 1-/2-Substituted-1H/-2H-[1,2,3]triazolo[4,5-G]phthalazine-4,9-dione compound, process for the preparation thereof and pharmaceutical composition comprising the same
  申请人：Choo Park Hea Young

  公开号：US20060217383A1

  公开（公告）日：2006-09-28

  The present invention relates to 1-/2-substituted-1H/-2H-[1,2,3]triazolo[4,5-g]phthalazine-4,9-dione compounds and their pharmaceutically acceptable salts, a process for preparing the compounds and a pharmaceutical composition comprising the compounds. The compounds are shown to effectively inhibit cell proliferation and are thus expected to be used for treatment or prevention or treatment of various cancers or as an ancillary(auxiliary) means of the same.

  本发明涉及1-/2-取代-1H/-2H-[1,2,3]三唑并[4,5-g]邻苯二酮-4,9-二酮化合物及其药用盐，一种制备该化合物的方法以及包含该化合物的药物组合物。这些化合物被证明能有效抑制细胞增殖，因此有望用于治疗或预防各种癌症，或作为辅助手段。
• 1-/2-substituted-1H/-2H-[1,2,3]triazolo[4,5-g]phthalazine-4,9-dione compound, process for the preparation thereof and pharmaceutical composition comprising the same
  申请人：EWHA University-Industry Collaboration Foundation

  公开号：US07160884B2

  公开（公告）日：2007-01-09

  The present invention relates to 1-/2-substituted-1H/-2H-[1,2,3]triazolo[4,5-g]phthalazine-4,9-dione compounds and their pharmaceutically acceptable salts, a process for preparing the compounds and a pharmaceutical composition comprising the compounds. The compounds are shown to effectively inhibit cell proliferation and are thus expected to be used for treatment or prevention or treatment of various cancers or as an ancillary(auxiliary) means of the same.

  本发明涉及1-/2-取代的1H/-2H-[1,2,3]三唑并[4,5-g]菲噻嗪-4,9-二酮化合物及其药学上可接受的盐、制备这些化合物的方法以及包含这些化合物的药物组合物。这些化合物被证明能够有效地抑制细胞增殖，因此预计可用于治疗或预防各种癌症，或作为同类药物的辅助手段。
• DIHYDROXYPHTHALAZINE, IHRE HERSTELLUNG UND VERWENDUNG
  申请人：Justus-Liebig-Universität Gießen

  公开号：EP3691011A1

  公开（公告）日：2020-08-05

  Die vorliegende Erfindung umfasst Dihydroxyphthalazine, deren Herstellung, sowie Zubereitungen, die Dihydroxyphthalazine enthalten. Weiterhin betrifft die Erfindung die Verwendung von Dihydroxyphthalazinen bzw. diese enthaltende Zubereitungen als Katholyte in organischen Redox-Fluß-Batterien.

  本发明涉及二羟基酞嗪、其制剂和含有二羟基酞嗪的制剂。此外，本发明还涉及二羟基酞嗪或含有二羟基酞嗪的制剂在有机氧化还原液流电池中作为阴离子的用途。
• Design, synthesis and biological evaluation of ezrin inhibitors targeting metastatic osteosarcoma
  作者：Mikell Paige、George Kosturko、Güllay Bulut、Matthew Miessau、Said Rahim、Jeffrey A. Toretsky、Milton L. Brown、Aykut Üren

  DOI：10.1016/j.bmc.2013.11.003

  日期：2014.1

  Respiratory failure due to pulmonary metastasis is the major cause of death for patients with osteosarcoma. However, the molecular basis for metastasis of osteosarcoma is poorly understood. Recently, ezrin, a member of the ERM family of proteins, has been associated with osteosarcoma metastasis to the lungs. The small molecule NSC 668394 was identified to bind to ezrin, inhibit in vitro and in vivo cell migration, invasion, and metastatic colony survival. Reported herein are the design and synthesis of analogues of NSC 668394, and subsequent functional ezrin inhibition studies. The binding affinity was characterized by surface plasmon resonance technique. Cell migration and invasion activity was determined by electrical cell impedance methodology. Optimization of a series of heterocyclic-dione analogues led to the discovery of compounds 21k and 21m as potential novel antimetastatic agents. (C) 2013 Elsevier Ltd. All rights reserved.
• Synthesis of 1-/2-substituted-[1,2,3]triazolo[4,5-g]phthalazine-4,9-diones and evaluation of their cytotoxicity and topoisomerase II inhibition
  作者：Jin Sung Kim、Hee-Kyung Rhee、Hyen Joo Park、Sang Kook Lee、Chong-Ock Lee、Hea-Young Park Choo

  DOI：10.1016/j.bmc.2008.02.049

  日期：2008.4

  Studies on antitumor heterocyclic quinones containing nitrogens revealed that the number and position of nitrogens on the heterocyclic ring have significance on cytotoxicity of quinones. In our continuous effort to find more cytotoxic quinone compounds, we designed triazolophthalazine analogues in order to introduce more nitrogens on the heterocyclic quinones. 1-/2-Substituted[ 1,2,3]triazolo[4,5-g] phthalazine-4,9-diones were synthesized by 1,3-dipolar addition of phthalazine-5,8-dione and 4-methoxybenzyl azide by modi. cation of previously reported method. The cytotoxicity of the synthesized compounds was evaluated by a SRB (sulforhodamine B) assay against nine types of human cancer cell lines and inhibition against topoisomerase II (Topo II) of them was assessed by a decatenation assay. Most of the synthesized compounds showed considerably higher cytotoxicity than that of doxorubicin. Also, topoisomerase II inhibitory activity of the tested compounds was higher than that of etoposide and IC50 values of the compounds were 19.4-64.5 mu M. (c) 2008 Elsevier Ltd. All rights reserved.